JP6480949B2 - 新規な縮合イミダゾベンゾチアゾール化合物 - Google Patents

新規な縮合イミダゾベンゾチアゾール化合物 Download PDF

Info

Publication number
JP6480949B2
JP6480949B2 JP2016559356A JP2016559356A JP6480949B2 JP 6480949 B2 JP6480949 B2 JP 6480949B2 JP 2016559356 A JP2016559356 A JP 2016559356A JP 2016559356 A JP2016559356 A JP 2016559356A JP 6480949 B2 JP6480949 B2 JP 6480949B2
Authority
JP
Japan
Prior art keywords
alkyl
imidazo
tert
butyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016559356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513825A5 (enExample
JP2017513825A (ja
Inventor
シンデー、プンドリク
スリヴァスタヴァ、サンジャイ
トゥリ、ダヴィンダール
ライ、デーパク
ジージェイ、プラシャント
デシュパンデ、シャイレシュ
グプタ、ラメーシュチャンドラ
チャウタイワレ、ヴィジャイ
ドゥト、チャイタンヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of JP2017513825A publication Critical patent/JP2017513825A/ja
Publication of JP2017513825A5 publication Critical patent/JP2017513825A5/ja
Application granted granted Critical
Publication of JP6480949B2 publication Critical patent/JP6480949B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
JP2016559356A 2014-03-27 2015-03-24 新規な縮合イミダゾベンゾチアゾール化合物 Expired - Fee Related JP6480949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1089MU2014 2014-03-27
IN1089/MUM/2014 2014-03-27
PCT/IB2015/052124 WO2015145336A1 (en) 2014-03-27 2015-03-24 Novel fused imidazobenzothiazole compounds

Publications (3)

Publication Number Publication Date
JP2017513825A JP2017513825A (ja) 2017-06-01
JP2017513825A5 JP2017513825A5 (enExample) 2018-04-12
JP6480949B2 true JP6480949B2 (ja) 2019-03-13

Family

ID=54194050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016559356A Expired - Fee Related JP6480949B2 (ja) 2014-03-27 2015-03-24 新規な縮合イミダゾベンゾチアゾール化合物

Country Status (30)

Country Link
US (2) US9908898B2 (enExample)
EP (1) EP3122755B1 (enExample)
JP (1) JP6480949B2 (enExample)
KR (1) KR102339610B1 (enExample)
CN (1) CN106414458B (enExample)
AR (1) AR099867A1 (enExample)
AU (1) AU2015237840B2 (enExample)
CA (1) CA2943098C (enExample)
CY (1) CY1121147T1 (enExample)
DK (1) DK3122755T3 (enExample)
EA (1) EA029745B9 (enExample)
ES (1) ES2707099T3 (enExample)
HR (1) HRP20190121T1 (enExample)
HU (1) HUE042493T2 (enExample)
IL (1) IL247955B (enExample)
LT (1) LT3122755T (enExample)
MX (1) MX368985B (enExample)
MY (1) MY193041A (enExample)
PH (1) PH12016501903B1 (enExample)
PL (1) PL3122755T3 (enExample)
PT (1) PT3122755T (enExample)
RS (1) RS58324B1 (enExample)
SG (1) SG11201607793RA (enExample)
SI (1) SI3122755T1 (enExample)
SM (1) SMT201900036T1 (enExample)
TR (1) TR201900735T4 (enExample)
TW (1) TWI648282B (enExample)
UA (1) UA121469C2 (enExample)
WO (1) WO2015145336A1 (enExample)
ZA (1) ZA201606598B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
DE102016209204A1 (de) 2016-05-27 2017-11-30 Robert Bosch Gmbh Vorrichtung zur Regelung mindestens eines Fluidstroms in einem Fahrzeug
KR102630959B1 (ko) * 2016-10-31 2024-01-29 엘지디스플레이 주식회사 유기 화합물과 이를 이용한 발광다이오드 및 유기발광다이오드 표시장치
CN106727538A (zh) * 2017-02-20 2017-05-31 潘连香 一种治疗2型糖尿病的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724566D0 (en) 1987-10-20 1987-11-25 Roussel Lab Ltd Chemical compounds
GB8908845D0 (en) 1989-04-19 1989-06-07 Roussel Lab Ltd Chemical compounds
WO1995029922A1 (en) * 1994-04-29 1995-11-09 Pharmacia & Upjohn Company Methanol derivatives for treatment of retroviral infections especially hiv infections
WO2002014321A1 (en) 2000-08-11 2002-02-21 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
CA2506796A1 (en) * 2002-11-25 2004-06-10 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
JP2009526037A (ja) * 2006-02-09 2009-07-16 ファイザー・リミテッド トリアゾロピリジン化合物
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物

Also Published As

Publication number Publication date
US20180127437A1 (en) 2018-05-10
MY193041A (en) 2022-09-23
AR099867A1 (es) 2016-08-24
US10227361B2 (en) 2019-03-12
ES2707099T3 (es) 2019-04-02
EP3122755B1 (en) 2018-11-07
TR201900735T4 (tr) 2019-02-21
IL247955A0 (en) 2016-11-30
PH12016501903A1 (en) 2017-01-09
UA121469C2 (uk) 2020-06-10
SMT201900036T1 (it) 2019-02-28
MX2016012535A (es) 2017-05-04
SI3122755T1 (sl) 2019-02-28
CN106414458A (zh) 2017-02-15
WO2015145336A1 (en) 2015-10-01
KR102339610B1 (ko) 2021-12-14
EA029745B9 (ru) 2018-08-31
TW201613941A (en) 2016-04-16
CY1121147T1 (el) 2020-05-29
CA2943098A1 (en) 2015-10-01
ZA201606598B (en) 2017-11-29
NZ724342A (en) 2021-02-26
EP3122755A1 (en) 2017-02-01
MX368985B (es) 2019-10-23
EA029745B1 (ru) 2018-05-31
PL3122755T3 (pl) 2019-05-31
TWI648282B (zh) 2019-01-21
CA2943098C (en) 2022-07-05
AU2015237840B2 (en) 2019-06-20
PH12016501903B1 (en) 2019-04-26
EA201691920A1 (ru) 2017-01-30
IL247955B (en) 2021-02-28
US9908898B2 (en) 2018-03-06
RS58324B1 (sr) 2019-03-29
CN106414458B (zh) 2019-10-29
AU2015237840A1 (en) 2016-09-29
US20170107233A1 (en) 2017-04-20
HUE042493T2 (hu) 2019-07-29
KR20160129089A (ko) 2016-11-08
HRP20190121T1 (hr) 2019-03-08
LT3122755T (lt) 2019-02-11
SG11201607793RA (en) 2016-10-28
JP2017513825A (ja) 2017-06-01
DK3122755T3 (en) 2019-02-18
PT3122755T (pt) 2019-01-30

Similar Documents

Publication Publication Date Title
US10227361B2 (en) Fused imidazobenzothiazole compounds
US20130059850A1 (en) Aza-indole derivatives useful as modulators of faah
US20190127381A1 (en) Substituted fused pyrimidinone compounds
US9963463B2 (en) Urea-substituted indanes as P38 map kinase inhibitors
WO2020153431A1 (ja) エステル化合物
TW201835041A (zh) 具β-腎上腺素促效劑及抗蕈毒活性化合物
TWI841671B (zh) 具有取代基之脲化合物
NZ724342B2 (en) Novel fused imidazobenzothiazole compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190208

R150 Certificate of patent or registration of utility model

Ref document number: 6480949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees